This systematic review and meta-analysis evaluated whether FDA-approved GLP-1 receptor agonists (GLP-1RA) used for obesity and/or type 2 diabetes were associated with histologic improvement in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). The analysis included six randomized controlled trials with 1555 participants, comparing GLP-1RAs-mostly semaglutide, with some tirzepatide and liraglutide-against placebo. The primary findings showed that GLP-1RAs were associated with a higher rate of MASH resolution without worsening of fibrosis compared with placebo. They also improved several histologic measures, including steatosis, ballooning degeneration, lobular inflammation, and nonalcoholic fatty liver disease activity score.

Fibrosis improvement was more nuanced. Across all included studies, GLP-1RAs showed a trend toward at least one-stage fibrosis regression without worsening MASH, but the overall result did not reach statistical significance. However, when studies involving patients with cirrhosis were excluded, fibrosis regression was significantly greater with GLP-1RAs than placebo. The authors suggest the benefits are likely driven largely by weight loss and note that safety outcomes, including serious adverse events and discontinuation rates, were similar to placebo. Overall, the study supports GLP-1RAs as a promising therapeutic option for MASH, while emphasizing the need for more research across fibrosis stages.

Reference: Siranart N, Thompson CC, Jirapinyo P. Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: a meta-analysis of randomized controlled trials. Hepatol Commun. 2026 Feb;10(2):e0871. doi: 10.1097/HC9.0000000000000871. PMID: 41543478.

The article argues that metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) represent a major, underrecognized global metabolic health threat that should be formally prioritized by the World Health Organization (WHO) and United Nations as part of the non-communicable disease agenda. Although more than a quarter of the world’s population is affected, MASLD/MASH remains largely invisible in global health policy despite its links to cancer, cardiovascular disease, diabetes, and preventable disease progression. The authors emphasize that MASLD and MASH should be understood as a single dynamic disease spectrum, not two separate conditions, and that focusing only on advanced disease misses a critical opportunity for prevention.

The article calls for stronger global action, including explicit WHO recognition, inclusion in National Coverage Determination guidance and action plans, measurable epidemiologic targets, integration into primary care and screening strategies, and policy changes tied to food environments, labeling, taxation, and digital health. It also stresses the need to include people living with MASLD/MASH in policy design, arguing that lived experience can highlight stigma, delayed diagnosis, and barriers to care. Overall, the message is urgent: without formal recognition and coordinated action, hundreds of millions of people may remain undiagnosed, unsupported, and at risk for avoidable progression.

Reference: Lazarus JV, Pessoa MG, Shawcross DL, et al. Name MASLD/MASH - and act on it. JHEP Rep. 2026 Jan 12;8(2):101674. doi: 10.1016/j.jhepr.2025.101674. PMID: 41725691; PMCID: PMC12919265.

This article reviewed recent metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) guidelines and guidance documents from around the world to identify where recommendations align, where they differ, and how to simplify them for busy clinicians. The authors evaluated 61 documents published from 2018 through early 2025 and found 46 areas of discordance, especially around screening, risk stratification with noninvasive tests, treatment of comorbidities, hepatocellular carcinoma surveillance, and use of newer MASH-targeted therapies. Through a four-round Delphi process with global experts, they developed consensus recommendations intended to make MASLD/MASH care more consistent and easier to implement across clinical settings.

The resulting guidance supports identifying high-risk patients, especially those with type 2 diabetes, obesity plus cardiometabolic risk factors, or persistent ALT/AST elevation, then using a stepwise noninvasive testing pathway such as fibrosis-4 index followed by vibration-controlled transient elastography or enhanced liver fibrosis testing when needed. The consensus also emphasizes lifestyle intervention, cardiometabolic risk management, individualized treatment of obesity and diabetes, and appropriate use of MASH-specific therapy where available. For resmetirom, the authors provide practical guidance on patient selection, use of noninvasive tests, safety monitoring, and assessing response or futility after treatment begins. Overall, the article aims to reduce confusion across guidelines and give clinicians a clearer, more usable pathway for diagnosing, monitoring, and managing MASLD/MASH.

Reference: Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025 Oct;169(5):1017-1032.e2. doi: 10.1053/j.gastro.2025.02.044. Epub 2025 Apr 11. PMID: 40222485.